Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Top Cited Papers
Open Access
- 7 December 2017
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 130 (23), 2463-2468
- https://doi.org/10.1182/blood-2017-08-801662
Abstract
During the last decade, the development of improved and novel approaches for the treatment of hemophilia A has expanded tremendously. These approaches include factor VIII (FVIII) with extended half-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab. Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa and the substrate factor X. By simultaneously binding enzyme and substrate, emicizumab mimics some part of the function exerted by the original cofactor, FVIII, in that it promotes colocalization of the enzyme–substrate complex. However, FVIII and the bispecific antibody are fundamentally different proteins and subject to different modes of regulation. Here, we will provide an overview of the similarities and dissimilarities between FVIII and emicizumab from a biochemical and mechanistical perspective. Such insight might be useful in the clinical decision making for those who apply emicizumab in their practice now or in the future, particularly in view of the thrombotic complications that have been reported when emicizumab is used in combination with FVIII-bypassing agents.Keywords
This publication has 46 references indexed in Scilit:
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- Factor VIII Light Chain Contains a Binding Site for Factor X That Contributes to the Catalytic Efficiency of Factor XaseBiochemistry, 2012
- The disappearing act of factor VIIIHaemophilia, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Insertion Loop 256−268 in Coagulation Factor IX Restricts Enzymatic Activity in the Absence but Not in the Presence of Factor VIIIBiochemistry, 2000
- Localization of a Factor X Interactive Site in the A1 Subunit of Factor VIIIaJournal of Biological Chemistry, 1997
- Model for the Factor VIIIa-dependent Decay of the Intrinsic Factor XasePublished by Elsevier BV ,1996
- Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.JCI Insight, 1993
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodiesBiochemistry, 1985